---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-120000"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:57:48.197669+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Acumen adds BTIG as ATM sales agent; $4.25M of $50M capacity used as of April 26

## Summary
- Added BTIG, LLC as a sales agent under the existing at-the-market (ATM) offering agreement.
- Amendment to Sales Agreement dated July 1, 2022; prospectus remains for up to $50M in common stock.
- As of April 26, 2023, sold 422,160 shares for aggregate proceeds of approx. $4.25M.
- Shares offered through BofA Securities, Stifel, and now BTIG as sales agents.

## SEC filing metadata
- accession: 0001193125-23-120000
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312523120000/0001193125-23-120000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312523120000/d467609d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-120000
- JSON: https://secwatch.observer/filing/0001193125-23-120000.json
- Plain text: https://secwatch.observer/filing/0001193125-23-120000.txt

## Key facts
- Material Agreements
  Acumen Pharmaceuticals, Inc. amended Sales Agreement with BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated, BTIG, LLC valued at aggregate offering price of up to $50,000,000 (effective 2023-04-27).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated, BTIG, LLC
  - Value: aggregate offering price of up to $50,000,000
  - Effective: 2023-04-27
  source text: On April 27, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into an amendment (“Amendment No. 1”) to the Sales Agreement, dated as of July 1, 2022 (the “Sales Agreement” and, as amended by Amendment No. 1, the “Amended Sales Agreement”) with BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated and BTIG, LLC (collectively referred to as “Sales Agents” and each individually a “Sales Agent”), pursuant to which the Company may sell its common stock, par value $0.0001 per share, from time to time through the Sales Agents in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1934, as amended (the “Securities Act”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000119312523120000/0001193125-23-120000-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.